The Ledger

71.7 billion dollars: that is what Cigna took in last quarter, the health services giant’s first earnings report under a new chief executive, and investors got a raised profit forecast to go with it. The Cigna Group reported second quarter 2026 total revenue of 71.7 billion dollars, up 7 percent year over year and above Wall Street’s 70.18 billion dollar estimate, with GAAP net income of 1.7 billion dollars, or 6.29 dollars per share, up from 1.5 billion dollars a year earlier, and adjusted income from operations of 2.1 billion dollars, or 7.78 dollars per share, beating the 7.60 dollar consensus. The results mark the first quarterly report under chief executive Brian Evanko, and the company raised its full year 2026 adjusted earnings per share guidance to at least 30.45 dollars, up 10 cents from its prior outlook of at least 30.35 dollars. The one caution sign: Cigna’s medical care ratio, the share of premium dollars spent on care, rose to 84.5 percent, which the company attributed mainly to prior year risk adjustments in its individual insurance plans, even as its pharmacy and health services arm Evernorth grew adjusted revenue to 61.5 billion dollars from 57.8 billion dollars a year earlier. Confidence: High, since the reported figures come directly from Cigna’s own SEC filing. Sources: Cigna Q2 2026 results, exhibit 99.1, U.S. Securities and Exchange Commission 8-K, As New CEO Takes Charge, Cigna Reports $1.7 Billion Quarterly Profit, Forbes.

0.64 dollars: that is how much two biotech deals will cost Johnson & Johnson in per share profit this year, and the company is telling investors it is worth it. Johnson & Johnson announced July 29, 2026 that it completed its 1 billion dollar cash acquisition of Firefly Bio, Inc., an oncology and RNA-therapeutics biotech, and separately entered strategic agreements with Sail Biomedicines that include 785 million dollars in initial payments, 465 million dollars of it an equity investment, up to 140 million dollars in milestone payments, and an exclusive option to acquire Sail outright for 2.58 billion dollars. In an 8-K filed the same day, J&J said the combined transactions will cut its 2026 adjusted operational earnings per share by about 64 cents, roughly 46 cents from Firefly and 18 cents from Sail, and lowered its full year adjusted earnings per share guidance to 10.96 to 11.11 dollars from a prior 11.60 to 11.75 dollars. Sail’s technology reprograms immune cells inside the body for what the companies call an “immune reset” against autoimmune disease, an in vivo CAR-T approach that skips the lab-grown cell manufacturing step most CAR-T therapies require. Confidence: High, since the deal terms and guidance cut come directly from Johnson & Johnson’s own 8-K filing and press releases. Sources: Johnson & Johnson Announces Collaboration with Sail Biomedicines, Johnson & Johnson, Johnson & Johnson Form 8-K, U.S. Securities and Exchange Commission.

4.5 billion dollars: that is how much a healthcare landlord now plans to spend on senior housing this year, after nearly doubling its own investment target mid-year. Ventas, Inc. reported second quarter 2026 results July 29, 2026 that beat Wall Street’s per share estimate by roughly 27 percent, driven by 2.2 billion dollars of senior housing investments the real estate investment trust closed during the quarter alone; Ventas raised its full year 2026 senior living investment target to more than 4.5 billion dollars, up 50 percent from its prior 3 billion dollar target, and said it has invested more than 8 billion dollars in its senior housing operating portfolio since 2024. The company also raised its full year earnings guidance, citing accelerating occupancy gains as new senior housing supply stays constrained nationally. Confidence: High on the reported figures, since they come directly from Ventas’ own earnings release; Medium on the precise earnings-per-share beat percentage, since it is drawn from market commentary rather than a line item in the release itself. Sources: Ventas Reports 2026 Second Quarter Results, Business Wire, Ventas, Inc. Form 8-K, U.S. Securities and Exchange Commission.

1 day: that is all the runway left for Miami’s academic health system and the nation’s largest insurer before hundreds of thousands of patients go out of network. As of July 30, 2026, UHealth, the University of Miami’s health system, and UnitedHealthcare remain without a new contract, with the July 31 deadline this issue has tracked since July 22 unchanged; UHealth’s negotiation page, last updated July 22, says UnitedHealthcare has not yet agreed to terms that protect patients’ care and that 94 percent of UnitedHealthcare’s claim denials are overturned on appeal, while UnitedHealthcare points to its own roughly 9 billion dollar quarterly profit and says its offer would bring UHealth’s rates in line with peer South Florida hospitals. Miss the deadline, and UHealth’s hospitals, clinics and physicians, anchored by the Bascom Palmer Eye Institute, go out of network August 1 for UnitedHealthcare’s commercial, Affordable Care Act exchange and Medicaid plans; a separate carve out keeps UnitedHealthcare’s Medicare Advantage Preferred Care Network members in network through August 31 regardless of the outcome. Confidence: High on the deadline and each side’s public position, since both come from the parties’ own pages; Low on whether a deal is struck in time. Sources: UHealth and UnitedHealthcare Negotiation, University of Miami Health System, Network Negotiations with Miami Health System (UHealth), UnitedHealthcare.

Undisclosed: that is the price tag on a deal that just combined two rival names into one company, and this Firefly is a telehealth practice, not the biotech Johnson & Johnson just bought. Included Health, a virtual-first health navigation and care company, announced July 29, 2026 that it struck a deal to acquire Firefly Health, a virtual-first primary and specialty care practice, to scale what the companies call an alternative to traditional employer health plans; financial terms were not disclosed, and the deal is expected to close in the third quarter of 2026. Included Health chief executive Owen Tripp said the combination reflects what the market needs from health coverage, positioning the combined company against traditional insurers as employers look for lower cost alternatives to fully insured commercial plans. Confidence: Medium, since the deal’s existence and expected close quarter come directly from the companies’ own statements, but financial terms remain undisclosed. Source: Included Health inks agreement to acquire Firefly Health to scale alternative health plan, Fierce Healthcare.

FRONTIER SCAN. 29: that is how many US plasma donor centers a global blood-products maker just closed, even as its profit jumped 28.7 percent. Grifols, the Spanish plasma-products company that is the largest single collector of blood plasma worldwide, reported first half 2026 results July 28, 2026 showing revenue up 2.6 percent to 3.6 billion euros and net profit up 28.7 percent to 227 million euros, even as it absorbs near term restructuring costs from 29 US donor center closures that the company says will not fully pay off until late 2026 or early 2027. The results land as Grifols executes a July 1, 2026 reorganization into a dual operating model that separates its US plasma division from the rest of its global structure, positioning US-sourced plasma to primarily supply the growing US market while plasma collected elsewhere serves Europe and the rest of the world, a shift the company says sharpens operational and financial independence ahead of a possible future partial listing of its US business. For a supply-chain player that sits upstream of every blood-product manufacturer and hospital transfusion service in the country, donor-center closures and restructuring costs are a business-cost story with no dedicated US trade publication tracking it closely; this scan confirms Grifols’ own newsroom as the most direct primary source, a branch of coverage this issue is touching for the first time. Confidence: High on the reported financial figures, since they come directly from Grifols’ own published results; Medium on the strategic rationale, since it rests on the company’s own characterization of its reorganization. Sources: Grifols press releases, Grifols, Grifols reorganizes its operating model to accelerate execution of its strategic roadmap, Grifols.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Firefly Bio, Inc.	Johnson & Johnson	Biotech, oncology and RNA therapeutics	$1 billion cash, completed July 29	Johnson & Johnson Completes Acquisition of Firefly Bio, Inc., Johnson & Johnson
Sail Biomedicines (option)	Johnson & Johnson	Biotech, in vivo CAR-T and autoimmune disease	$785 million initial payments including $465 million equity, plus up to $140 million milestones; option to acquire for $2.58 billion total	Johnson & Johnson Announces Collaboration with Sail Biomedicines, Johnson & Johnson
Firefly Health	Included Health	Digital health, virtual-first primary and specialty care	Undisclosed; expected to close Q3 2026	Included Health inks agreement to acquire Firefly Health, Fierce Healthcare
Multiple senior housing properties (Q2 2026 aggregate)	Ventas, Inc.	Senior housing real estate	$2.2 billion closed in Q2 2026; full-year target raised to more than $4.5 billion from $3 billion	Ventas Reports 2026 Second Quarter Results, Business Wire

Cigna, Johnson & Johnson and Ventas all reported today or yesterday; Healthcare Realty Trust reports after today’s market close. Privia Health, agilon health, Oscar Health and Clover Health cluster in early August.